✦ LIBER ✦

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

✍ Scribed by Jin, Jie; Wang, Jian-Xiang; Chen, Fei-Fei; Wu, De-Pei; Hu, Jiong; Zhou, Jian-Feng; Hu, Jian-Da; Wang, Jian-Min; Li, Jian-Yong; Huang, Xiao-Jun; Ma, Jun; Ji, Chun-Yan; Xu, Xiao-Ping; Yu, Kang; Ren, Han-Yun; Zhou, Yu-Hong; Tong, Yin; Lou, Yin-Jun; Ni, Wan-Mao; Tong, Hong-Yan; Wang, Hua-Feng; Mi, Ying-Chang; Du, Xin; Chen, Bao-An; Shen, Yi; Chen, Zhu; Chen, Sai-Juan

Book ID: 120468984
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 395 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70152-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of gemtuzumab ozogamicin on survi

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

✍ Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bo 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 287 KB

Reduced-intensity conditioning versus st

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

✍ Martin Bornhäuser; Joachim Kienast; Rudolf Trenschel; Andreas Burchert; Ute Hege 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 350 KB

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB